

Commercial Medicines Unit

NHS England and NHS Improvement

2nd Floor

Rutland House

Runcorn

Cheshire

WA7 2ES

3 October 2019

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  |  |

**Invitation to offer for NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other monoclonal Antibodies, and Fondaparinux**

**Offer reference number: CM/PHR/16/5527**

**CM/PHR/16/5527/01: NHS Framework for the NHS** **North Of England Region, Branded Medicines, Tranche B, 1 March 2020 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

**CM/PHR/16/5527/02: NHS Framework for the NHS North Of England Region, Branded Medicines Annual Tranche, Cytokine Modulators and other monoclonal antibodies, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months**

**CM/PHR/16/5527/03: NHS Framework agreement for Fondaparinux**

**London, 1 March 2020 to 31 August 2021 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

**South of England, 1 March 2020 to 31 August 2020 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

**Midlands and East, 1 March 2020 to 28 February 2021 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

The NHS Commissioning Board (Operating Under the Name of NHS England) (‘Authority’) invites offers for the above-mentioned goods and/or services as defined in Document No.03 Framework Agreement and Terms and Conditions. Offers shall be made subject to the terms of:

Document No.01 This covering letter

Document No.02 Terms of offer

Document No.03 Framework Agreement and Terms and Conditions

Document No.04 Contract technical specification

Document No.05a(i) Product listing and usage – CM/PHR/16/5527/01

Document No.05a(ii) Product listing and usage – CM/PHR/16/5527/02

NHS England and NHS Improvement



Document No.05a(iii) Product listing and usage – CM/PHR/16/5527/03

Document No.05b(i) Selectt offer schedule – CM/PHR/16/5527/01

Document No.05b(ii) Selectt offer schedule – CM/PHR/16/5527/02

Document No.05b(iii) Selectt offer schedule – CM/PHR/16/5527/03

Document No.05c Offer schedule – CM/PHR/16/5527

Document No.05d Selectt offer schedule instructions

Document No.06 Form of offer

Document No.07a Quality control technical sheet

Document No.07b Guidance for performing a pharmaceutical quality assessment of licensed medicines for the NHS

Document No. 08 Confidential information schedule

Document No. 09 Instructions on completing the tender

all of which constitute this Invitation to offer.

If any of the documents constituting the Invitation to offer is missing please contact the undersigned immediately via the Bravosolution messaging portal.

The Authority does not bind itself to accept the lowest offer or any offer at all and reserves the right to accept an offer either in whole or in part, each item being for this purpose treated as offered separately. The Authority reserves the right to conclude a framework agreement for the supply of the goods and/or services with more than one Offeror.

I would like to draw your attention to the following important points when completing and submitting your offer:

1. All offers must be written in English.

2. All offers must be submitted subject to and in accordance with the documentation comprising the Invitation to offer. Save where the Offerors are instructed to provide information, the documentation comprising the Invitation to offer must not be amended in any way.

3. All offers must be loaded onto the Commercial Medicines Unit’s eTendering portal <https://nhsengland.bravosolution.co.uk/web/login.html>

4. Offers must be open for 90 days.

5. Offers must be fully completed and available on the designated website no later than **1300** on **7 November 2019**.

I must also draw your attention to the enclosed Form of offer where all the requirements for completing and submitting an offer can be found. Failure to comply with these instructions may result in your offer being rejected.

I hope that the above instructions are clear but please contact the undersigned via the Bravosolution messaging portal if there is anything you wish to clarify.

Yours faithfully



Michelle Clarke

Operations Adviser and Developing Commercial Practitioner

Branded, Biosimilars and IV Fluids Procurement Support